# EDGAR Filing Document

**Accession Number:** 0001790340
**File Stem:** 0001790340-25-000063
**Filing Date:** 2025-6
**Character Count:** 5569
**Document Hash:** 15a632d795f6699426ef54b87f992a9f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001790340-25-000063.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001790340-25-000063

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250613

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immuneering Corp
- **CENTRAL INDEX KEY:** 0001790340
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40675
- **FILM NUMBER:** 251048628

**BUSINESS ADDRESS:**
- **STREET 1:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-500-8080

**MAIL ADDRESS:**
- **STREET 1:** 245 MAIN STREET, SECOND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

?xml version='1.0' encoding='ASCII'? imrx-20250613

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

__________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 13, 2025**

__________________________________

**Immuneering Corporation**

**(Exact name of Registrant as Specified in Its Charter)**

__________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40675** | **26-1976972** |
| **(State or Other Jurisdiction of Incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

**245 Main St.**

**Second Floor**

**Cambridge, MA 02142**

**(Address of principal executive offices) (Zip Code)**

**(617) 500-8080**

**(Registrant's telephone number, include area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Class A common stock, par value $0.001 per share | IMRX | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 13, 2025, Immuneering Corporation (the "Company") held its Annual Meeting of Stockholders. A total of 24,866,430 shares of the Company's Class A common stock were present in person or represented by proxy at the meeting, representing approximately 69.1 percent of the Company's outstanding Class A common stock as of the April 17, 2025 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 21, 2025.

Item 1 — Election of three Class I directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | Votes | Votes | Broker Non- |
| NOMINEE | Votes FOR | AGAINST | WITHHELD | Votes |
| Ann E. Berman | 13,230,831 | 0 | 1,625,960 | 10,009,639 |
| Diana F. Hausman, M.D. | 13,564,145 | 0 | 1,292,646 | 10,009,639 |
| Thomas J. Schall, Ph.D. | 14,630,652 | 0 | 226,139 | 10,009,639 |

---

Item 2 — Ratification of the appointment of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.

---

| | | | |
|:---|:---|:---|:---|
| | | Votes | |
| Votes FOR | Votes AGAINST | ABSTAINED | Broker Non-Votes |
| 24,648,142 | 191,884 | 26,404 | 0 |

---

Based on the foregoing votes, Ann E. Berman, Diana F. Hausman, M.D. and Thomas J. Schall, Ph.D. were elected as Class I directors and Item 2 was approved.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | IMMUNEERING CORPORATION | IMMUNEERING CORPORATION |
| Date: June 16, 2025 | By: | /s/ Michael D. Bookman |
|  |  | Name: Michael D. Bookman |
|  |  | Title: Chief Legal Officer and Secretary |

---